Pancreatic Cancer-targeting Adenovirus Vector Construction Service
Creative Biolabs has always contributed to the development of life sciences by providing scientists with a variety of high-quality biological tools. In order to promote the advancement of tumor gene therapy technology, we have made unremitting efforts to launch pancreatic cancer-targeted adenoviral vector (AV) construction services. Our adenoviral vector construction platform with strict standards can meet customer's requirements. No matter what difficulties you have encountered in the relevant research work, you can contact us to get your customized service.
Pancreatic Cancer-targeting Gene Therapy
Pancreatic cancer is the third leading cause of cancer death in western countries, and its incidence has remained high in the past few decades. There is still no suitable solution to the poor prognosis. This is mainly due to the metastatic nature of this tumor and the lack of systematic and effective treatment. Previous reports suggest that pancreatic cancer will be the second leading cause of cancer deaths in 2030. In order to change this bad situation, scientists need to develop new treatment methods, of which gene therapy is one of the most promising methods.
Figure 1. Improvements in vector delivery to and targeting of cancer cells.1
There are several notable features of gene therapy for pancreatic cancer. First, it requires efficient gene vectors that can transfer a large number of genes with more controllable expression time. Second, it is necessary to accurately locate the target during treatment, because the pancreas is a kind of organs that are closely associated with surrounding blood vessels and other organs. Strict control of gene delivery during gene therapy is necessary. Finally, due to the high invasiveness and increasing rate of pancreatic cancer, it is necessary to consider how to dispose some growth factors that enhance tumor metastasis in treatment.
Adenovirus Vector for Gene Therapy
Oncolytic adenoviruses that are capable of specifically replicating in cancer cells have shown good results in the treatment of various cancer models. These viruses only need to transduce a small number of cells to initiate oncolysis, initiate the replication and spread to other cancer cells, eventually leading to the disappearance of tumor mass. Adenovirus based on human serotype 5 is one of the most ideal vectors for gene therapy. It can produce and infect a variety of cells at high titers both in vivo and in vitro. At present, in order to allow adenovirus to specifically infect cancer cells without affecting other normal cells, there are two ways to construct. The first is to introduce a mutation into the adenovirus E1A gene, and the mutated gene is functionally complemented by genetic mutations in cancer cells, such as p53 mutations. In the second method, transcription of the adenovirus E1 gene is restricted to cancer cells by a tumor or tissue-specific promoters such as the prostate-specific antigen, survivin, midkine, and telomerase reverse transcriptase promoters. In addition, adenoviral vectors can carry and express various genes for treating cancer, including tumor suppressor genes p53, p16, single-chain antibodies, antisense DNase and the like.
Our Pancreatic Cancer-Targeting Adenovirus Engineering Capabilities
Clinical studies of oncolytic adenoviruses have shown that increasing the targeting of adenoviral vectors is key to improve the efficiency of cancer treatment and ensure patient safety. We generally construct targeted adenoviral vectors by directly incorporating ligands for target cell surface receptors into fibrin. Scientists have demonstrated that a pancreatic cancer-targeting sequence, SYENFSA (SYE), which was selected from the adenovirus library by screening against the AsPC-1 pancreatic cancer cell line, significantly enhanced the gene transduction efficiency of the adenoviral vector in pancreatic cancer cell lines but not in normal cells.
Vector Design Options
We support multiple adenoviral vector formats:
- Replication-deficient adenoviruses
- Conditionally replicative adenoviruses (CRAd)
- Fully oncolytic adenoviruses
Each design is tailored to your research or therapeutic objectives.
Targeting Enhancement Technologies
To maximize tumor specificity and delivery efficiency, we offer:
- Adenovirus vector modification
- Ligand-mediated targeting
- Receptor retargeting strategies
- Capsid engineering
Payload Engineering
We enable flexible integration of therapeutic payloads, including:
- Tumor suppressor genes
- Immunomodulatory genes
- Antibody fragments
- RNA-based therapeutics
Promoter and Expression Optimization
We optimize expression systems to achieve:
- Tumor-specific expression
- Controlled gene expression
- Enhanced therapeutic efficacy
Tumor-Specific Targeting Strategies
1. Genetic Engineering of Viral Replication
We design conditionally replicative adenoviruses by modifying key genes such as:
-
E1A/E1B deletions or mutations
- Enable replication only in tumor cells with defective pathways
2. Tumor-Specific Promoter Control
To enhance tumor selectivity, we incorporate promoters such as:
- hTERT promoter
- Survivin promoter
- Midkine promoter
These promoters restrict gene expression specifically to cancer cells.
3. Fiber Knob Modification and Receptor Retargeting
We enhance viral tropism through:
- Fiber knob engineering
- Ligand insertion
- Receptor-specific targeting modifications
This enables efficient infection even in cells with low native adenovirus receptor expression.
4. Pancreatic Cancer-Specific Targeting Peptides
We integrate targeting peptides such as:
- SYENFSA (SYE) peptide
This modification significantly improves adenoviral transduction efficiency in pancreatic cancer cell lines such as AsPC-1.
Why Adenovirus for Pancreatic Cancer Gene Therapy?
High transduction efficiency, large packaging capacity, and intrinsic oncolytic potential make adenovirus the preferred vehicle for solid tumors.
Proven Targeting Strategy: The SYENFSA (SYE) Peptide
Our scientists identified a 7-mer peptide SYENFSA via phage display biopanning against AsPC-1 pancreatic cancer cells. When displayed on the adenoviral fiber knob, SYE significantly enhances gene transfer efficiency in multiple PDAC cell lines while preserving negligible transduction in normal pancreatic ductal or hepatic cells. This translates to a higher therapeutic index for both replicative and non-replicative vectors.
Replication-competent Adenoviruses
Conditionally replicative adenoviruses (CRAds) exploit cancer-specific mutations or place E1 under tumor-specific promoters. They lyse tumor cells and spread within the lesion, amplifying the therapeutic effect. Ideal for direct intratumoral injection in preclinical models.
Replication-deficient Vectors
E1/E3-deleted adenoviruses offer a safe platform for transient, high-level expression of therapeutic transgenes (cytokines, antibodies, CRISPR-Cas9). Perfect for combination strategies where controlled payload delivery is essential.
Dual Targeting (Transcriptional + Transductional)
We combine tissue-specific promoters with fiber modifications to achieve "double-lock" specificity, drastically reducing hepatotoxicity and broadening the therapeutic window — a critical requirement for systemic administration studies.
What You'll Receive
| Deliverable | Description |
|---|---|
| Customized Vector Design | Tailored adenoviral construct |
| High-Titer Viral Stock | Ready-to-use viral particles |
| Validation Data | Functional and targeting validation |
| Technical Report | Detailed experimental documentation |
| Ongoing Support | Expert consultation and optimization |
Why Choose Creative Biolabs?
01 Decades of Expertise in Gene Therapy Tools
Creative Biolabs has been at the forefront of gene therapy research, delivering thousands of custom viral vector projects to academic and industry clients worldwide. Our dedicated adenovirus platform combines deep biological understanding with rigorous manufacturing standards, ensuring that every vector — from simple reporter constructs to complex dual-targeted oncolytic viruses — meets the highest benchmarks for reproducibility and performance.
02 End-to-End Quality Control
We understand that vector quality directly impacts experimental outcomes. Every production batch undergoes comprehensive QC testing, including:
- Titer determination by both TCID50 and qPCR for precise dosing
- Replication-competent adenovirus (RCA) testing to ensure safety
- Endotoxin and sterility testing for in vivo compatibility
- Sequencing verification across all engineered regions
03 Flexible Service Models
Whether you require a single research-grade batch or multiple lots with identical specifications for longitudinal studies, we scale accordingly. Our modular approach allows you to choose from:
- Standard vector construction with defined targeting elements
- Fully customized design incorporating your preferred promoter, transgene, or targeting peptide
- Optional in vitro validation packages with side-by-side comparison against control vectors
- Expedited timelines for time-sensitive projects
04 Dedicated Scientific Support
From the initial consultation to post-delivery troubleshooting, you will work directly with experienced virologists and molecular biologists who understand the nuances of pancreatic cancer research. We assist with experimental design, help interpret validation data, and provide guidance on in vivo administration routes and dosing strategies — ensuring that your vector performs as expected in your specific application.
Frequently Asked Questions
Q: How do I choose between replication-competent and replication-deficient vectors for my study?
A: Replication-competent (oncolytic) vectors are ideal when you want direct tumor lysis and intratumoral spread, suitable for single-agent efficacy studies or in situ immunization. Replication-deficient vectors are preferred when you need precise control over transgene expression levels, especially when delivering immunomodulators or when systemic administration is intended. Our scientific team can help match your goals to the optimal backbone.
Q: What off-target risks exist with targeting peptides, and how do you control them?
A: Our targeting strategies are validated using a panel of human primary cells (pancreatic ductal, hepatocytes, fibroblasts) alongside cancer cell lines. For transcriptionally targeted vectors, we further confirm that no E1 expression occurs in non-malignant cells. If desired, we can provide comprehensive specificity reports prior to large-scale production.
Q: Can I combine a tumor-specific promoter with a targeting peptide and also arm a therapeutic gene?
A: Yes. Our cloning platform supports triple modifications: promoter-driven E1 (for CRAds) or transgene cassette, plus fiber-knob peptide display. The adenovirus genome accommodates up to ~7.5 kb of foreign DNA, allowing combination strategies such as hTERT-promoter-controlled replication plus SYE targeting plus GM-CSF expression.
Q: What quality control tests are performed before release?
A: Each lot undergoes titer determination (TCID50 and qPCR), sterility (14-day bacterial/fungal), mycoplasma detection, endotoxin measurement (<1 EU/mL), and replication-competent adenovirus (RCA) testing by serial passage. For vectors containing transgenes, expression is confirmed by Western blot or functional assay.
Creative Biolabs has accumulated a wealth of experience through the success of one project after another. We have introduced different products and services with a rigorous scientific attitude and promoted the continuous development of gene therapy technology. Adenoviral vector construction services targeting pancreatic cancer are once again overcoming the technical difficulties and improving your experimental efficiency with precise targeting and transfection stability. If you have some questions or difficulties, you can contact us by email or send us an inquiry to find a complete solution.
Reference
- Tessarollo N G, Domingues A C M, Antunes F, et al. Nonreplicating adenoviral vectors: improving tropism and delivery of cancer gene therapy. Cancers, 2021, 13(8): 1863. https://doi.org/10.3390/cancers13081863 Distributed under Open Access license CC BY 4.0, without modification.
